Sanofi (NASDAQ:SNY) Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its position in Sanofi (NASDAQ:SNY) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,811 shares of the company’s stock after buying an additional 1,216 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $6,116,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of SNY. Abel Hall LLC boosted its stake in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares during the period. PDS Planning Inc boosted its stake in shares of Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares during the period. Financial Advocates Investment Management boosted its stake in shares of Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after purchasing an additional 206 shares during the period. Angeles Investment Advisors LLC boosted its stake in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after purchasing an additional 210 shares during the period. Finally, Keudell Morrison Wealth Management boosted its stake in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SNY. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Performance

Shares of SNY stock opened at $54.47 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a fifty day moving average price of $51.65 and a 200 day moving average price of $52.61. The company has a market cap of $138.24 billion, a P/E ratio of 21.88, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.